NCT00954226 2025-09-05
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
3 trialsNCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT01316757 2018-02-26
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Phase 2 Completed